GeoVax Labs (NASDAQ:GOVX – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect GeoVax Labs to post earnings of ($1.29) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
GeoVax Labs Stock Performance
Shares of GOVX stock opened at $1.95 on Monday. The firm’s 50 day moving average is $2.50 and its 200 day moving average is $2.57. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on GOVX. Roth Capital upgraded shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. Roth Mkm started coverage on GeoVax Labs in a research note on Tuesday, July 16th. They set a “buy” rating and a $20.00 price objective on the stock. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Finally, Noble Financial lifted their target price on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.67.
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Further Reading
- Five stocks we like better than GeoVax Labs
- How to Invest in Insurance Companies: A Guide
- California Resources Stock Could Be a Huge Long-Term Winner
- What are earnings reports?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- How Can Investors Benefit From After-Hours Trading
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
